Search

Displaying results 2461 - 2470 of 10000 in total
  1. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    [L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628] … [A274848, A274853, A274858] Elevated APRIL levels are often observed in inflammatory disorders, including immunoglobulin A nephropathy (IgAN).

  2. Drug

    Trichlormethiazide

    go.drugbank.com/drugs/DB01021
    ApprovedVet approved

    A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)

  3. Drug

    Remoxipride

    go.drugbank.com/drugs/DB00409
    ApprovedWithdrawn

    [A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512] … Remoxipride is an atypical antipsychotic agent that is specific for dopamine D<sub>2</sub> receptors.

  4. Drug

    Acitretin

    go.drugbank.com/drugs/DB00459
    ApprovedInvestigational

    An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate.

  5. Drug

    Benznidazole

    go.drugbank.com/drugs/DB11989
    ApprovedInvestigational

    [L939] It is the first treatment made available in the United States for Chagas disease. … Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017.

  6. Drug

    Givinostat

    go.drugbank.com/drugs/DB12645
    ApprovedInvestigational

    [L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD). … In the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss.

  7. Drug

    Clavulanic acid

    go.drugbank.com/drugs/DB00766
    ApprovedInvestigationalVet approved

    [A182228]When it is combined with amoxicillin, clavulanic acid is frequently known as Augmentin, Co-Amoxiclav, or Clavulin.[L7880,L7904,L7910] … [T665] Clavulanic acid is derived from the organism Streptomyces clavuligerus.

    Mixtures: CROXILEX 1.2G IV ENJEKSİYON İÇİN TOZ İÇEREN FLAKON, Amoklavin 1000 mg/200 mg IV Enjeksiyonluk/İnfüzyonluk Çözelti Hazırlamak İçin Toz ve Çözücü
  8. Drug

    rdESAT-6

    go.drugbank.com/drugs/DB21906
    Approved

    rdESAT-6 is a recombinant dimer of _Mycobacterium tuberculosis_ early secretory antigenic target used as an ingredient in the diagnostic agent SIILTIBCY along with [rCFP-10].[L53638]

  9. Drug

    Darvadstrocel

    go.drugbank.com/drugs/DB16581
    ApprovedInvestigationalWithdrawn

    [L39759] It is the first mesenchymal stem cell therapy approved in Europe for this therapeutic indication. … It is indicated for the treatment of complex perianal fistulas in adult patients with non-active or mildly active luminal Crohn’s disease when fistulas have shown an inadequate response to at least one

  10. Drug

    mRNA-1283

    go.drugbank.com/drugs/DB22668
    ApprovedInvestigational

    [L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna. … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from